Ado-trastuzumab emtansine

{
  "id": "MLC-T-ONC-000263",
  "term": "Ado-trastuzumab emtansine",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat certain patients with HER2-positive breast cancer that has already been treated with trastuzumab and a type of anticancer drug called a taxane. It is also being studied in the treatment of other types of cancer. Ado-trastuzumab emtansine contains a monoclonal antibody called trastuzumab that binds to a protein called HER2, which is found on some breast cancer cells. It also contains an anticancer drug called DM1, which may help kill cancer cells. Ado-trastuzumab emtansine is a type of antibody-drug conjugate. Also called Kadcyla and T-DM1.",
    "An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers."
  ],
  "abbreviation": "T-DM1",
  "synonyms": [
    "Kadcyla",
    "T-DM1",
    "trastuzumab-MCC-DM1",
    "trastuzumab-DM1",
    "trastuzumab-MCC-DM1 antibody-drug conjugate",
    "trastuzumab emtansine",
    "trastuzumab-MCC-DM1 immunoconjugate",
    "ado trastuzumab emtansine"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ado-trastuzumab-emtansine/"
}